PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Stock Information for PDS Biotechnology Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PDS Biotechnology Corporation

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ("FDA")
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.